Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate

Michael E. O'Dwyer, Michael J. Mauro, Carolyn Blasdel, Melanie Farnsworth, Gwen Kurilik, Yi Ching Hsieh, Motomi Mori, Brian J. Druker

Research output: Contribution to journal › Article › peer-review

104 Scopus citations

Fingerprint

Dive into the research topics of 'Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds